Borean Pharma AS, (Aarhus, Denmark) has established an extended and coherent proprietary protein technology platform that allows it to use tetranectin (a native human plasma and tissue protein) as a vehicle for the creation of advanced fully human antibody analogue products, readily tailored to meet specific therapeutic needs.
Evolva in contract negotiations with the US government for funding to advance nootkatone against Zika
Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States